Radiation therapy

Hematology/Oncology Clinics of North America

Volumn 18, Issue 1, 2004, Pages 1-12

  Jeremic, Branislav ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT;

BEAM THERAPY; BRONCHOSCOPY; BRONCHUS CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DYSPNEA; ESOPHAGUS DISEASE; ESOPHAGUS HEMORRHAGE; HEMOPTYSIS; HISTOLOGY; HUMAN; HYPOXIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MEDIASTINOSCOPY; MEDICAL RESEARCH; METASTASIS; MICROENVIRONMENT; MORTALITY; ONCOLOGY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSENSITIVITY; RADIOSURGERY; REVIEW; SPINAL CORD DISEASE; STEREOTAXIC SURGERY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR BIOPSY;

EID: 1042274834     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00143-6     Document Type: Review

References (77)

1. Morrison R., Delley T.J., Cleland W.P. The treatment of carcinoma of the bronchus. A clinical trial to compare surgery and supervoltage radiotherapy. Lancet. I:1963;683-684.
2. Smart J. Can lung cancer be cured by irradiation alone? JAMA. 195:1966;1034-1035.
3. Dose specification for reporting external beam therapy with photons and electrons. ICRU Report. 29:1978;3-13.
4. Mountain C.F. A new international staging system for lung cancer. Chest. 89:1986;225S-233S.
5. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
6. Perez C., Stanley K., Grundy G.et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the Radiation Therapy Oncology Group. Cancer. 50:1982;1091-1099.
7. Perez C.A., Bauer M., Edelstein S.et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 12:1986;539-547.
8. Perez C.A., Pajak T.F., Rubin P.et al. Long term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 59:1987;1874-1881.
9. Holsti L.R., Matson K. A randomized study of split-course radiotherapy of lung cancer: long term results. Int J Radiat Oncol Biol Phys. 6:1980;977-981.
10. Petrowich Z., Stanley K., Cox J.D.et al. Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer. 48:1981;1335-1340.
11. Cox J.D., Yesner R., Mietlowski W.et al. Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung. Cancer. 44:1979;94-98.
12. Petrowich Z., Mietlowski W., Ohanian M.et al. Clinical report on the treatment of locally advanced lung cancer. Cancer. 40:1977;72-77.
13. Withers H.R. Biological basis for altered fractionated schemes. Cancer. 55:1985;2086-2095.
14. Cox J.D., Azarnia N., Byhardt R.W.et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with > 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555.
15. Saunders M., Dische S., Barrett A.et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol. 52:1999;137-148.
16. Dillman R.O., Seagren S.L., Propert K.J.et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 323:1990;940-945.
17. Dillman R.O., Herndon J., Seagren S.L.et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 88:1996;1210-1215.
18. LeChevalier T., Arriagada R., Tarayre M.et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst. 84:1992;58. [letter].
19. Sause W.T., Scott C., Taylor S.et al. Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst. 87:1995;198-205.
20. Sause W., Kolesar P., Taylor S. IVet al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 117:2000;358-364.
21. Schaake-Konig C., van der Bogaert W., Dalesio O.et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
22. Jeremic B., Shibamoto Y., Acimovic L.J.et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 13:1995;452-458.
23. Jeremic B., Shibamoto Y., Acimovic L.j.et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 14:1996;1065-1070.
24. Furuse K., Nishikawa H., Takada Y.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
25. Furuse K., Hosoe S., Masuda N.et al. Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT) [abstract]. Proc Am Soc Clin Oncol. 19:2000;459. Abstract 1893.
26. Curran W.J. Jr., Scott C., Langer C.et al. Phase III comparison of sequential Vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [abstract]. Proc Am Soc Clin Oncol. 19:2000;484a. Abstract 1891.
27. Komaki R., Seiferheld W., Curran W.et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410) [abstract]. Proc Am Soc Ther Radiol Oncol. 42:2000;113. Abstract 5.
28. Lau D., Leigh B., Gandara D.et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol. 19:2001;442-447.
29. Albain K.S., Crowley J.J., Turrisi A.T. IIIet al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II study, SWOG 9019. J Clin Oncol. 20:2002;3454-3460.
30. Vokes E.E., Herndon J.E. II, Crawford J.et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol. 20:2002;4191-4198.
31. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomized trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer. 63:1991;265-270.
32. A Medical Research Council (MRC) randomized trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer. 65:1992;934-941.
33. Falk S.J., Girling D.J., White R.J.et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomized controlled trial. BMJ. 325:2002;465-471.
34. Jeremic B., Bamberg M. External beam radiation therapy for bronchial stump recurrence of non-small-cell lung cancer after complete resection. Radiother Oncol. 64:2002;251-257.
35. Green N., Melbye R.W. Lung cancer: retreatment of local recurrence after definitive irradiation. Cancer. 49:1982;865-868.
36. Jackson M.A., Ball D.L. Palliative retreatment of locally recurrent lung cancer after radical radiotherapy. Med J Aust. 147:1987;391-394.
37. Montebello J.F., Aron B.S., Manatunga A.K.et al. The reirradiation of recurrent bronchogenic cracinoma with external beam irradiation. Am J Clin Oncol. 16:1993;482-488.
38. Gressen E.L., Werne-Wasik M., Cohn J.et al. Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol. 23:2000;160-163.
39. Okamoto Y., Murakami M., Yoden E.et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys. 52:2002;390-396.
40. Mendiondo O.A., Dillon M., Beach L.J. Endobronchial brachytherapy in the treatment of recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 9:1983;579-582.
41. Seagren S.L., Harrell J.H., Horn R.A. High dose rate intraluminal irradiation in recurrent endobronchial carcinoma. Chest. 88:1985;810-814.
42. Mehta M.P., Shahabi S., Jarjour N.N.et al. Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys. 17:1989;847-851.
43. Bedwinek J., Petty A., Bruton C.et al. The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 22:1991;23-30.
44. Sutedja G., Baris G., Schaake-Koning C.et al. High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 24:1992;551-553.
45. Gauwitz M., Ellerbroek N., Komaki R.et al. High dose endobronchial irradiation in recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 23:1992;397-400.
46. Gustafson G., Vicini F., Freedman L.et al. High dose rate endobronchial brachytherapy in the management of primary and recurrent bronchogenic malignancies. Cancer. 75:1995;2345-2350.
47. Delclos M.E., Komaki R., Morice R.C.et al. Endobronchial brachytherapy with high-dose-rate remore afterloading for recurrent endobronchial lesions. Radiology. 201:1996;279-282.
48. Kelly J.F., Delclos M.E., Morice R.C.et al. High-dose-rate endobrobchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 48:2000;697-702.
49. Antonodou D., Coliarakis N., Synodinou M.et al. Clinical Radiation Oncology Hellenic Group. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;915-922.
50. Senzer N. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. Semin Oncol. 29(6 Suppl 19):2002;38-41.
51. Komaki R., Lee J.S., Kaplan B.et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer; preliminary results. Semin Radiat Oncol. 12(1 Suppl 1):2002;46-49.
52. Leong S.S., Tan E.H., Fong K.W.et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 21:2003;1767-1774.
53. Armstrong J.G., Burman C., Leibel S.A.et al. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 26:1993;685-689.
54. Armstrong J.G., Raben A., Zelefsky M.et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 44:1997;17-22.
55. Robertson J.M., Ten Haken R.K., Hazuka M.B. Dose escalation for non small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1079-1085.
56. Kwa S.L., Lebesque J.V., Theuws J.C.et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 42:1998;1-9.
57. Graham M.V. Prediciting radiation response. Int J Radiat Oncol Biol Phys. 39:1997;561-562.
58. Yorke E. Advantages of IMRT for dose escalation in radiation therapy for lung cancer. Med Phys. 28:2001;1291.
59. Nagata Y., Negoro Y., Aoki T.et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 52:2002;1041-1046.
60. Whyte R.I., Crownover R., Murphy M.J.et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 75:2003;1097-1101.
61. Kubo H.D., Hill B.C. Respiration gated radiotherapy treatment: a technical study. Phys Med Biol. 41:1996;83-91.
62. Ohara K., Okumura T., Akisada M.et al. Irradiation synchronized with respiration gate. Int J Radiat Oncol Biol Phys. 17:1989;853-857.
63. Sontag M.R., Merchant T.E., Burnham B.et al. Clinical experience with a system for pediatric respiratory gated radiotherapy. Int J Radiat Oncol Biol Phys. 42:1998;140-146.
64. Johnson L.S., Hadley S.W., Pelizzari C.A. A video-based technique to gate radiotherapy treatments for respiration. Int J Radiat Oncol Biol Phys. 42:1998;139-145.
65. Mageras G.S., Yorke E., Rosenzweig K.et al. Fluoroscopic evaluation of diaphragmatic motion reduction with a respiratory gated radiotherapy system. J Appl Clin Med Phys. 2:2001;191-200.
66. Wong J.W., Sharpe M.B., Jaffray D.A.et al. The use of active breathing control (ABC) to minimize breathing motion during radiation therapy. Int J Radiat Oncol Biol Phys. 39:1997;164-169.
67. Stromberg J.S., Sharpe M.B., Kini V.R.et al. Active breathing control (ABC) for Hodgkin's desease: reduction in normal tissue irradiation with deep inspiration and implication for treatment. Int J Radiat Oncol Biol Phys. 42:1998;140-145.
68. Wong J.W., Sharpe M.B., Jaffray D.A.et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys. 44:1999;911-919.
69. Hanley J., Debois M.M., Raben A.et al. Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat Oncol Biol Phys. 36:1996;188-194.
70. Mac Manus M.P., Hicks R.J., Ball D.L. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 92:2001;886-895.
71. MacManus M.P., Hicks R.J., Matthews J.P. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 50:2001;287-293.
72. Mac Manus M.P., Hicks R.J., Matthews J.P.et al. Positron emission tomography is superior to CT scanning for response-assessment after radical radiotherapy/chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol. 21:2003;1285-1292.
73. Erdi Y.E., Rosenzweig K., Erdi A.K. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 62:2002;51-60.
74. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 55:2000;317-324.
75. Choi N.C., Fischman A.J., Niemierko A. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 54:2002;1024-1035.
76. Erdi Y.E., Macapinlac H., Rosenzweig K.E. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 27:2000;861-866.
77. Coleman N.C., Cumberlin R.L. Translational research in radiation oncology. Int J Radiat Oncol Biol Phys. 49:2001;885-890.